Pacira BioSciences (NASDAQ:PCRX) Given New $24.00 Price Target at Barclays

Pacira BioSciences (NASDAQ:PCRX) had its price objective lifted by Barclays from $17.00 to $24.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on PCRX. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright raised their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price objective for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. Finally, Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $24.05 on Friday. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -11.85 and a beta of 0.80. The firm has a 50-day simple moving average of $23.16 and a 200-day simple moving average of $18.58. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors have recently made changes to their positions in the stock. State of Wyoming increased its position in shares of Pacira BioSciences by 8.0% during the fourth quarter. State of Wyoming now owns 6,566 shares of the company’s stock valued at $124,000 after acquiring an additional 487 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock valued at $68,000 after purchasing an additional 513 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Pacira BioSciences by 3.1% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after purchasing an additional 794 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of Pacira BioSciences by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after purchasing an additional 918 shares during the period. Finally, Sterling Capital Management LLC boosted its stake in shares of Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock valued at $26,000 after purchasing an additional 1,208 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.